Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Flu is rising rapidly, driven by a new variant. Here's what to know - 2These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
- 3'Spending more on gas than groceries:' Rising fuel prices drive more San Antonio families to the Food Bank amid Iran war
- 4Gen Z workplace stereotypes were TV’s favorite punchline in 2025
- 5NATO official says members often aren't buying weapons together, and it's a mistake
- An ex-FBI agent analyzes what we learned from Savannah Guthrie's 'Today' show interview amid the search for her mother Nancy
- Novo Nordisk cuts Wegovy price in South Africa for a second time
- Vinicultural Investigation: A Survey of \Enjoying Fine Vintages\ Wine sampling
- The Significance of Health Projects in Senior Protection.
- ‘Serving is not just a place’: Bayside Church Granite Bay reimagines annual mission amid conflict in Mexico
- The Artemis II launch is tonight. Here's how to watch it live.
- Why most Jewish Israelis back the death penalty for terrorists
- How to track NASA’s Artemis II and Orion’s journey to the moon
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
